

4baseCare raises Rs 90 Cr in Series B round to scale AI powered precision oncology platform

27 January 2026 | News

Making precision oncology more inclusive and accessible to cancer patients across geographies



Bengaluru-based startup 4baseCare, a precision oncology company building population-relevant clinico-genomic intelligence, has announced the first close of its Series B funding round, raising Rs 90 crore co-led by renowned investors Ashish Kacholia, and Lashit Sanghvi with participation from existing investor Yali Capital.

The company had earlier raised Rs 50 crore in Series A funding led by Yali capital and participated by Infosys.

The funds from this first close will be used to expand 4baseCare's hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia, with the vision of making precision oncology more inclusive and accessible to cancer patients across geographies.

4baseCare will also accelerate the development and deployment of its AI-driven clinical decision support solutions, including OncoTwin Insights, to help oncologists derive actionable treatment insights from real-world clinico-genomic and outcomes-linked datasets. OncoTwin was recently selected for the MSK iHub program of Memorial Sloan Kettering Cancer Centre, New York, USA.

Ashish Kacholia and Lashit Sanghvi, Co-leads for the round, said, "4baseCare is building a powerful genomics and AI-driven clinical intelligence platform for inclusive precision oncology. With strong hospital partnerships enabling access to world-class diagnostics for patients in clinical settings, the company is well positioned to scale across emerging markets and expand its delivery model for maximum patient benefit"

Hitesh Goswami, CEO of 4baseCare, said, "This funding will help us scale globally while building OncoTwin as an AI-driven decision support platform that learns from real-world clinico-genomic outcomes and supports oncologists with faster, more confident insights."